January 8, 2013 at 11:16 am (Antipsychotics, Bipolar Disorder, Depression, Loose Screws Mental Health News, Mental Health/Illness, Schizophrenia)
Tags: Adasuve, agitation, Alexza Pharmaceuticals, asthma, Bipolar Disorder, Books, bronchospasm, C-reactive protein, COPD, CRP, Depression, I'd Like to Apologize to Every Teacher I Ever Had, Japan, Loose Screws Mental Health News, loxapine, marijuana, Medscape, mental health, mental illness, NICS, pot, psychosis, public school teachers, reading, Schizophrenia, teens, Tony Danza
An antipsychotic inhalation powder has been approved by the FDA for the treatment of agitation in adults with schizophrenia or bipolar I disorder. While loxapine (brand name: Adasuve) by Alexza Pharmaceuticals acts rapidly, the side effects include “bronchospasm and increased mortality in elderly patients with dementia-related psychosis,” according to Medscape. In case you don’t know, bronchospasm can lead to acute respiratory problems in people with lung disease, asthma, or COPD (chronic obstructive pulmonary disease).
Plans are for the drug to only be accessible through a medical facility with the ability to treat bronchospasms.
In related and somewhat interesting news, the Medscape article also notes that 3.2 million people in the U.S. are being treated for schizophrenia or bipolar I. “Of these, approximately 90% will develop agitation during the course of their illness.”
That’s an incredibly high number of people who develop agitation. Just sayin’.
According to an article in U.S. News & World Report, patients in a study dealing with depression seemed to have high levels of C-reactive protein (CRP), a marker for increased risk of heart and inflammatory disease. The lead researcher notes that “people with increased CRP have a two- to threefold risk of depression.” It is not clear whether CRP causes depression or is simply a sign of it. Increased levels of CRP tend to be seen in obese patients and those with chronic diseases.
“More than 21 million Americans suffer from depression, a leading cause of disability, according to Mental Health America.”
Note: the 2011 estimate of those residing in the U.S. stands at more than 311 million.
Depression is increasing among Japan’s public school teachers.
“A report by the Ministry of Education, Sports, Culture, Science and Technology shows that in 2011, around 5,200 public school teachers had to go on sick leave due to various mental illnesses, including severe depression.”
The Japan Daily Press article also notes:
“The study also highlights the fact that the main reason for the increasing depression is a school environment that puts too much workload and pressure on the teachers that they cannot have a healthy work-life balance anymore, much less deal with students, their guardians and the paper work that comes with all of these. (emphasis mine)”
I recently finished a book by actor Tony Danza called I’d Like to Apologize to Every Teacher I Ever Had in which he chronicles his yearlong stint in Philadelphia’s inner city public school system. He echoes some of these sentiments as well. After trying to teach his students, he notes that it is difficult not to get involved in their personal lives as well. In the Epilogue, Danza writes:
“…I can only do so much. Where does teaching stop, and start? Where should it? I don’t really know. To engage my students, I found that I had to become engaged in their lives, their problems, and their futures. That connection was what made the job the most rewarding. Yet it was also the intensity of that involvement that, by the end of the year, had made the job of teaching so much tougher than I’d ever expected.”
It seems that Japan’s public school teachers are no different from American public school teachers.
Although 38 states require mental health background checks, only a quarter of states actually report their statistics to the federal NICS (National Instant Criminal Background Check System).
And surprise, according to a recent study, pot could lead to psychosis in teens or teens who smoke pot can later develop psychosis. I find it interesting that teens were actually evaluated after smoking pot.
April 9, 2009 at 3:20 pm (Anticonvulsants, Antidepressants, Antipsychotics, Depression, Medicine/Meds, Mental Health/Illness, Personal, Schizophrenia)
Tags: Adverse Effects, Anticonvulsants, Antidepressants, big pharma, counseling, doctors, dopamine, drug withdrawal, drugs, escitalopram, Lamictal, lamotrigine, Lexapro, med withdrawal, medication, medication withdrawal, meds, neurotransmitters, paranoia, paranoid, patient, Pharma, pharma drugs, pharmaceutical, pharmaceutical companies, psych, psych drugs, psych meds, psychiatry, psychology, psychotropics, Schizophrenia, schizophrenic, serotonin, side effects, suicidal ideation, suicidal thoughts, Suicide, withdrawal
My brain isn’t functioning today quite honestly so my apologies if the following makes no sense whatsoever. It’s long and I ended up rambling.
Lately, I’ve been thinking about whether there are any benefits to using pharmaceutical drugs. I have blogger friends who are very much anti-pharmaceuticals anything, try to avoid drugs as much as possible but take them if necessary, or think pharmaceutical drugs are a Godsend.
I’m still trying to figure out where I stand.
Pharmaceutical companies are in the business of making money. It is not to their advantage to put out completely shoddy products that do not work. I’m sure many of them bury negative data and findings that do not shed a positive light on their drugs but if something works overall, they’ll put it out there. I don’t believe the doctors who are involved in these trials are all dirty, rotten sell-outs. Some of them are very well-meaning and honest who work to make these drugs as effective as possible. Call me naïve if you like but I just can’t bring myself to believe there are more greedy docs who skew results than there are those who are concerned with advancement.
I don’t think twice about popping Excedrin Migraine when I’ve got a painful, debilitating migraine; I have no problem taking naproxen (aka Aleve) when I’ve got menstrual cramps, and taking ibuprofen isn’t an issue if I have severe muscle pain. I don’t question the safety of these drugs. I’ve used them for so long, they’ve proven to be relatively safe for me (not everyone can tolerate those drugs) and efficacious. The safety risk of taking Excedrin Migraine sometimes outweighs the benefits of not taking it. (Note: I only speak of adults in terms of ingesting this kind of medication.I don’t believe developing bodies, such as youngsters, are able to handle medication that can significantly affect mood.)
When it comes to psych meds, I am not anti-medication. Psych meds should be taken on a case-by-case basis. There are some people who consider these meds to be a life-saver while others complain that it has made them miserable and worsened their lives. This is the gamble people take when choosing to ingest a psych med—most people don’t know that. Trouble is, most people don’t know when the stakes are high enough to take that risk.
I shouldn’t be in a position to judge anyone but when I hear people taking antidepressants based on circumstances—a job loss, failed relationship, loss of a life—I worry that it’s unnecessary. We are becoming a nation that is more reliant on “quick fixes” rather than developing coping mechanisms. It’s easier to pop a pill and dull your emotions than it is to face problems, tackle issues head on, and learn to work your way through it. Case in point: rising unemployment hasn’t slowed sales of antidepressants or sleeping pills.
- I have an aunt who was a violent paranoid-schizophrenic. She was placed in a mental institution and drugged up the wazoo. Now, she’s basically existing; the lights are on but no one’s home. The drugs have killed her. She’s alive but not really.
- My father was a non-violent paranoid-schizophrenic. It got to the point where we needed to medicate him to get him on track. The medication helped him to function “normally” but his thought processes and physical ability was significantly slowed. He once told me that he felt useless because my mother was busting her butt at work to pay for my college and he was basically an invalid because his mental illness had prevented him from being able to work. He died 4 months later. A few days after the funeral, my mom began to find his psych meds hidden all around the house. I often wonder if the drugs killed him.
- Another aunt (this is all on the paternal side of the family) also became a paranoid-schizophrenic. She was a brilliant woman who was basically reduced to moving from place to place to the point where she eventually became homeless and could not hold down a job. She disappeared for a while but during one cold winter, was found and brought into a homeless shelter. She was placed on meds and her cognitive functions returned despite the fact that her speech was sometimes garbled. She traveled the world, went on cruises and various excursions. The change was remarkable. Psych meds improved her life and saved her—the benefits of the drugs outweighed the side effects.
As I withdraw from Lamictal, I am curious to see who I am without this drug. Will my creative juices flow freely once again or are they now somewhat hindered? Will my cognitive functioning correct itself or will I forever suffer from problems? Will my short-term memory loss issues smooth out or will I still suffer from intermittent forgetfulness? I have some side effects that may remain with me for a while or perhaps forever (though I hope not) but seeing others fully recover after taking drugs for 10 times longer than I have gives me hope.
I feel the majority of my progress has come from intensive counseling and being infused with the truths as laid out in the Bible. I’d say 90% of my progress has been due to counseling. I give the meds 10%. You can tell I don’t place much stock in them. But they’ve helped to cut down on the mixed episodes.
So far, I haven’t had any suicidal thoughts are behaviors that are out of the ordinary. (Thank GOD.) I’ve been dealing with a mild depression but that stems from basing my worth based off of my career rather than any biological imbalances. The last time I suffered a severe depression, I was on Lexapro (if that tells you anything).
I’ve gotten a lot of resistance and concern from family members who question my decision to come off of the medication. They’ve seen a miraculous change in me and attribute it to being on meds. Meds aren’t a cure-all. They don’t see the counseling and shifting of thought processes going on that has helped me to develop coping mechanisms. Meds may help people “cope” but they don’t develop the tools needed to cope.
I’ve decided that I’ll probably give that Christian psychiatrist a call. My counselor recommended him and she said that he’s very neutral on meds and doesn’t shove them on anyone. I mentioned that I wasn’t sure if anyone would accept me as a patient only to lose me in the end—she insisted he wouldn’t mind. The intake cost is hefty but since I was able to temp a few days for my job this week—I’m not permanently returning, I can swing it.
Which brings me back to my position on psych meds: I said it earlier but I think it’s a case-by-case basis. In my personal life, I’ve seen the benefits outweigh the side effects and I’ve seen the side effects outweigh the benefits. And I’ve seen benefits (not necessarily beneficial) as a result of side effects. Psychiatry is the biggest medical guessing game of all medical specialties. There are no certainties, and there’s no one medication that works best for everyone. Pharmaceutical companies make it a point to put the disclaimer on the patient information sheet that they’re not exactly sure HOW these drugs work. All that stuff about serotonin, dopamine, and neurotransmitters is pure speculation when it comes to depression. You’ll have me convinced about chemical imbalances once I can get a MRI and blood test done. Until then, it’s all trial-and-error.
So if I do suffer from relapses while withdrawing from this medication and it gets to the point where I may need to be hospitalized, I’m not averse to remaining on the drug. Better to be alive and on a psych drug than dead because I was determined not to use it at risk to my safety. If I end up having to stay on the drug, the future of giving birth to children will seem a bit more uncertain.
February 9, 2009 at 10:51 am (Loose Screws Mental Health News)
Tags: abortion, American Psychological Association, APA, Bipolar Disorder, blues, British Journal of Psychiatry, chronic depression, clinical depression, Daily Mail, Depression, Journal of Psychiatric Research, Loose Screws Mental Health News, mental health, mental health news, mental illness, Philadelphia Weekly, Schizophrenia
I decided to publish a “Loose Screws Mental Health News” post even though I said a few weeks back I wouldn’t do it anymore. Eh, can I change my mind? “Yes I can.”
According to the Journal of Psychiatric Research
and the British Journal of Psychiatry
, women who had abortions suffered from more mental problems than women who did not. However, a report from the American Psychological Association asserts that there is no connection between abortion and mental health issues
. (via CBN News; photo from solarnavigator.net)
I can’t imagine that there is no connection. Considering an abortion is stressful enough. I would think actually following through with it would induce a whole new set of problems.
I’m sure Liz Spikol has probably linked to this article already but the Philadelphia Weekly had a great cover story about a man’s struggle to take care of his mentally ill older brother who has bipolar disorder with psychosis. It’s a long read but well worth it and very touching. It reminded me a little bit of what my mother and I went through with my father which made me very empathetic.
An article in the Daily Mail reports that some scientists think depression can be good for people:
There are, they say, more benefits from the blues. Being sad can leave victims stronger, better able to cope with life’s challenges, and can lead to great achievements.
And their claims may stack up historically with Sir Winston Churchill, Abraham Lincoln, Sir Isaac Newton and Beethoven all suffering from some form of depression.
A growing number of psychiatrists are now questioning whether doctors and drug companies are too keen to treat the condition with pills that may have side effects and also harm the evolution of human emotion.
I think there’s some truth to that and I wholeheartedly agree with the third paragraph. However, I wonder if they’re simply addressing normal depression aka “the blues” rather than clinical or chronic depression.
January 19, 2009 at 5:36 pm (Bipolar Disorder, Medicine/Meds, Mental Health/Illness, Schizophrenia, Statistics)
Tags: bipolar, Bipolar Disorder, disorders, mental health, mental illness, mental illnesses, relatives, Schizophrenia, schizophrenic, Seroquel, Zyprexa
According to researchers at Stockholm's Karolinska Institute, schizophrenia and bipolar disorder may have common genetic causes. Researchers studied 9 million Swedish people during a 30-year period and discovered that "relatives of people with schizophrenia or bipolar disorder had an increased risk of both disorders." The study may also suggest that "the two conditions may simply be different manifestations of the same disease."
The article from Reuters also points out that Seroquel and Zyprexa are used to treat both disorders, which may lead people in the psychiatric industry to further investigate the link between the two illnesses. Here are some interesting discoveries from the study:
* First-degree relatives (parents, siblings, or offspring) of people with either schizophrenia or bipolar disorder were at increased risk for both of these conditions.
* If a sibling had schizophrenia, full siblings were nine times more likely than the general population to have schizophrenia and four times more likely to have bipolar disorder.
* If a sibling had bipolar disorder, they were eight times more likely to have bipolar disorder and four times more likely to have schizophrenia.
* Half siblings who shared the same mother were 3.6 times more likely to have schizophrenia if their half sibling had schizophrenia and 4.5 times more likely to have bipolar disorder if their half sibling had bipolar disorder. Half siblings who shared the same father had a 2.7-fold increase in schizophrenia risk and a 2.4-fold increase in bipolar disorder.
* Adopted children with a biological parent with one of the disorders had a significant increase in risk for the other.
Creepy. My father's schizophrenia didn't begin to manifest itself until he was in his 40s. The same is true for my two other aunts as well. It may be silly but I live in fear that I may have the same problem. I'll eventually get a psychiatric advance directive in place just in case that day ever comes. After seeing three family members with debilitating schizophrenia/paranoia, sometimes it gets to the point where the benefits of being drugged up outweigh the risks.
Mood rating: 6
July 28, 2008 at 12:01 pm (Bipolar Disorder, Medicine/Meds, Schizophrenia)
Tags: Alexza Pharmaceuticals, AZ-004, bipolar, Bipolar Disorder, drugs, inhalation, inhale, loxapine, medication, psych drugs, psych meds, psychotropic, Risperdal, Schizophrenia, Staccato stystem
Oh no they didn’t. From Alexza Pharmaceuticals’ recent PR:
Alexza Pharmaceuticals, Inc. announced today that it has initiated its second Phase 3 clinical trial with AZ-004 (Staccato(R) loxapine). AZ-004 is an inhalation product candidate being developed for the treatment of acute agitation in patients with schizophrenia or bipolar disorder. Alexza believes the novel, non-invasive nature and rapid pharmacokinetic (PK) properties resulting from inhaled loxapine administration via the Staccato system (click on the photo to the right to see an enlargelarement) have the potential to make AZ-004 a viable product to treat acute agitation.
The supposed benefits:
- Rapid onset
- Ease of use
- Consistent dose and particle size
- Broad applicability
Is this pharmaceutical company really developing a product to treat schizophrenic and bipolar disorder symptoms by inhaling? I thought the injectable Risperdal was bad. Check out how the Staccato system works. It blows my mind that psych drugs are being developed for injection and inhalation.
July 25, 2008 at 2:30 pm (Bipolar Disorder, Celebrities, Depression, Diagnoses, Mental Health/Illness)
Tags: Abraham Lincoln, Alanis Morissette, anorexia, anorexic, Beethoven, Billy Joel, bipolar, Bipolar Disorder, Brooke Shields, bulimia, bulimic, Celebrities, Charles Dickens, Courtney Love, depressed, Depression, Drew Carey, eating disorder, Edgar Allen Poe, Elton John, Eric Clapton, Harrison Ford, Janet Jackson, Jim Carrey, John Nash, Kurt Cobain, Ludwig Von Beethoven, Marie Osmond, Mark Twain, Marlon Brando, mental health, mental illness, mentally ill, Mike Wallace, NIN, Nine Inch Nails, Patty Duke, Paula Abdul, postpartum depression, Princess Diana, Ray Charles, Schizophrenia, Sheryl Crow, Terry Bradshaw, Trent Reznor, Van Gogh, Vincent Van Gogh
The local NAMI chapter has literature all over a counter at my local library. One of the pieces of literature actually was a 5×7 index card with a list of famous people who struggled with mental illness. It was kind of interesting so I figured I’d share it. Some I’d already known about; others were a bit of a surprise. How did they figure out who had bipolar disorder back in the 1800s?
Read the rest of this entry »
July 8, 2008 at 5:30 pm (Blogs, Celebrities, Depression, Mental Health/Illness)
Tags: bipolar, Bipolar Disorder, Celebrities, celebrity, death, depressed, Depression, famous, mental health, mental illness, Pop-Crunch Show, Schizophrenia, Suicide
The Pop-Crunch Show has a list of 135 Famous People Who Struggled with Depression. I sit on the fence and think that it should probably be retitled "135 Famous People Who Struggled with Mental Health Issues."
But then again, we could throw nearly every celebrity in there, huh? I’m bummed that Tom Cruise isn’t on the list.
May 16, 2008 at 5:22 pm (Mental Health/Illness, Music)
Tags: lyrics, Madonna, Schizophrenia, voices
Voices start to ring in your head
Tell me what do they say
Distant echoes from another time
Start to creep in your brain
So you play madness like it’s convenient
You do it so often that you start to believe it
You have demons so nobody can blame you
But who is the master and who is the slave?
— Madonna, "Voices" —
DISCLAIMER: No, I don’t hear voices. But this song always makes me wonder what my father heard when he suffered from schizophrenia.
April 19, 2008 at 11:30 pm (Blogs, Mental Health/Illness, Personal, Statistics)
Tags: Antidepressants, bipolar, Bipolar Disorder, blog, blogging, Blogs, bpd, Christian blogs, Christian mental health blogs, Christians, Depression, depression introspection, education, Furious Seasons, Google bomb, health, Lamictal, linking, links, mental health, mental illness, My Bipolar Journey, My Life with Bipolar Disorder, Pharma, Psychiatric Drug Withdrawal and Recovery, readers, Risperdal, Roller Coaster, Schizophrenia, Seroquel, sites, soulful sepulcher, weblogs, websites, withdrawal, Zyprexa
From one of Furious Seasons’s latest posts:
Mental Health Blogs Going Bye-Bye?
As I noted earlier, there’s a spate of mental health blogs that are going on hiatus of some kind. Now, it’s my sad duty to report that Gianna Kali’s Bipolar Blast blog is going on an indefinite hiatus as well. You can read her post "Quitting?" for the details. Bottom line: all those years of very high doses of psych meds seem to have injured her body. I cannot even begin to send her enough good wishes. I cannot even begin to express my disgust with some of the bad doctors she ran into over the years.
Also, the Psych Survivor blog, written by a man I only know as Mark, was taken down a few weeks ago, and from what I gather he is in the hospital with heart problems. His was/is a good and strident voice on these issues we all care about and his work is missed.
All of this kind of makes me feel glum, since the two people above had been at the blogging game for well over a year and I sensed that they’d both be around long-term. These are people I care about and it sucks that they won’t be the presence they once were.
Why is it that mental health blogs are so difficult to do and keep going? Why is it so hard for them to find the substantial audiences they deserve? The Internet is crowded with blogs about politics, technology, gadgets, gossip and parenting and many of these seem to do quite well and have huge audiences and long lives, despite the fact that many of them are merely echoes of one another. Are readers of blogs that simple-minded that all they need is the latest news and opinion on Apple’s or Microsoft’s latest bit of software or Obama’s or Hillary’s latest gaffe?
You’d think in a country where 10 percent of the population is on anti-depressants and another 5 percent to 10 percent is likely on some other psych med that there would be a substantial audience for these issues (regardless of what one makes of the dominant mental health paradigm), especially given how wildly popular neuroscience is on the Net. It makes me wonder if we all–and here I include myself–have done something wrong in how we analyze these issues (are we too contrarian?) or if we all simply haven’t been crowded out of the big search engines (that’s how most people find mental health information online) because the Net is so over-populated with pharma sites and allied pro-pharma health websites. I can certainly say that the mainstream media–which usually loves writing about characters on the Net who push against life’s many intellectual tides–has given very little attention to sites like this one, despite the fact that sites like mine have been a very real service to many in the media.
Or maybe the mainstream approach to mental health care is right and the public is just trying to tell us something.
What do you think?
I’ll tell you what I think.
Read the rest of this entry »
April 16, 2008 at 11:23 am (Antipsychotics, Bipolar Disorder, Children, Loose Screws Mental Health News, Medicine/Meds, Mental Health/Illness, Suicide)
Tags: Antidepressants, bipolar, Bipolar Disorder, Children, drugs, farm animals, foster homes, generic, J&J, Johnson & Johnson, mania, medication, mental health, mental illness, polygamous sect, psych drugs, psych meds, Risperdal, Schizophrenia, Suicide, suicide rates, Teva, Teva Pharmaceutical Industries
If the state gets its way, hundreds of children could be put in foster homes, in what could be a wrenching cultural adjustment that may require intensive counseling.
Wow. That's all I can say. How do you place 400 different children in foster homes and ensure they'll get proper care? You can't.
September 17, 2007 at 10:38 am (Schizophrenia)
Tags: mental illness, Schizophrenia, schizophrenic
I came across One Man’s Blog that has a post about what it’s like to deal with schizophrenia. I’ve been told that the video is creepy (I haven’t had the heart to watch it) so brace yourself to be freaked out. I just can’t imagine what it’s like to struggle with that kind of illness.
UPDATE: The link should work now.
June 25, 2007 at 4:01 pm (Antidepressants, Antipsychotics, Bipolar Disorder, Depression, Loose Screws Mental Health News, Medicine/Meds, Mental Health/Illness, Pharma, Schizophrenia, Suicide)
Tags: Bipolar Disorder, Depression, disabilities, disability, dosage, FDA, job, Johnson & Johnson, Lexapro, manslaughter, Mary Winkler, murder, psychiatry, Risperdal, Schizophrenia, settlement, Starbucks, Suicide, teenagers, teens, zoloft
Let’s start off small and build up, shall we?
A blog I came upon, Providentia, has a post on the suicide rate in Kentucky over a 10-year period. Male schizophrenics have the highest rate of suicide. The leading methods of suicide in the state are firearm use, overdose, and hanging.
Mary Winkler, the preacher’s wife who killed her husband, has been moved from jail to a mental health facility
, where she will serve the remainder of her three-year sentence.
East meadow, a poster on the drugs.com message board, asks about Lexapro’s correlation to suicide
. Her sister committed suicide while on Lexapro and questions whether the Lexapro might have affected her in that way. As a former Lexapro user, I can empathize with the change in her sister’s behavior.
The Depression Calculator
: see how much depression is costing your company and see if treatment is worth your while. I went through it for kicks and basically, I walked away feeling like it cost too much to hire someone with depression, especially if I were running a small business. Blah.
Apparently, bipolar disorder is
covered under the Americans with Disabilities Act (ADA). Starbucks is settling an $85,000 lawsuit with Christine Drake
, a former Starbucks employee who suffers from bipolar disorder. It seems that Drake’s first manager was willing to work with her “psychiatric impairment” and allow her to gain “extra training and support.” Then, get this:
“But, during her third year, new management told her she was “not Starbucks material,” refused to continue the accommodation and ultimately fired her for discriminatory reasons, the agency alleged.”
Starbucks probably put up one helluva fight, but in the end, they’ve tried to put a good face and good spin on the situation:
Starbucks agreed to pay Drake $75,000 and donate another $10,000 to the Disability Rights Legal Center, which provides legal representation for low-income people with disabilities facing discrimination, as part of the settlement.
“The facts of this case illustrate how relatively minor accommodations are often all that disabled people need to be productive members of the work force,” said the EEOC’s San Francisco district office director, Joan Ehrlich. “It is important that all of Starbucks’ managers understand their legal duties regarding disabled employees and provide them with the tools necessary to succeed. This is in everyone’s best interest.”
Ms. Drake, who seems to be more than capable of handling a job well, has probably eeked out several years of a barista’s salary from the Starbucks suit.
I’m amused, but it’s not necessarily a good thing.
Johnson & Johnson is gearing up to put Risperdal for children on the market. I’m sure other blogs have beat me to the punch on this, but I just came across this info and found it absolutely retarded. (But what do drug companies care?)
The FDA has approved “expanded use” for Risperdal in teenagers who suffer from schizophrenia and the short-term treatment of bipolar mania in kids ages 10-17. I’m leery enough about antidepressants in kids let alone antipsychotics.
“J&J said the agency has not requested the company perform any additional studies, implying that it need only agree with the FDA on acceptable labeling for the expanded uses in order to gain final approval.”
I wasn’t sure what “expanded use” was so I looked it up. This was the best I could come up with:
“Applications for a new or expanded use, often representing important new treatment options, are formally called “efficacy supplements” to the original new drug application.”
Well, I didn’t know what efficacy supplements were so I looked that up too:
“The legislative history indicates that this provision was directed at certain types of efficacy supplements (i.e., supplemental applications proposing to add a new use of an approved drug to the product labeling).”
So – correct me if I’m wrong – it sounds like the studies performed that led up to this “expanded use” are not as rigorously evaluated by the FDA as the initial studies that allowed the drug to be released on the market in the first place. It just seems like a company and the FDA simply need to agree on “acceptable labeling.” So if we’re following the theory that I’m still correct, the FDA doesn’t follow up on the clinical trials performed on these children, they just agree with J&J on the “acceptable labeling.” Doesn’t that thought make you feel all warm and fuzzy inside about your health?
On the subject of children and psychotropic medications, 12-year-old Christopher Pittman shot and killed his grandparents and then set their house on fire in November 2001 all while on an adult dosage of Zoloft
. It looks like the drama is still playing out in June 2007
According to CourtTV.com, Pittman suffered from hallucinations while on the 200 mg dose and while in jail, displayed symptoms of mania.
“Three years after the killings, Pittman was tried in adult court and convicted of murder. He was sentenced to 30 years in prison. He was then 15 years of age.”
No doubt Pittman should be held responsible for what occurred, especially if he admitted to the killings (which he did). However, the situation raises a few questions. First of all, why was he on 200 mg of Zoloft when he was TWELVE? Why wasn’t he considered mentally ill and placed in a mental health facility? I could go on and on. While Pittman “did the crime and needs to do the time,” why isn’t the doctor who prescribed this not present in any of the reported stories? If this incident was 2001, it can only be worse for antidepressants and other psych meds today.
May 4, 2007 at 3:55 pm (Celebrities, Depression, Loose Screws Mental Health News, Mental Health/Illness)
Tags: breast-feeding, Depression, diabetes, DISC1, gene, gene mutation, hormonal therapy, Joan Rivers, Kathleen Kendall-Tackett, Kathy Cronkite, menopause, Mike Wallace, moms, new moms, postpartum depression, Schizophrenia, stress, The Edge of Darkness
Advance apologies for sounding like I’m in a cynical mood. I’m working on something today that I’m not fond of.
An article in Newsday (by the Associated Press) says that researchers are becoming hopeful that hormonal therapy can ward off mental health decline in menopausal women
, such as dementia. It seems that previous research found that hormonal therapy produced negative results, but the new research suggests that timing may be the defining factor. Older women in the later stages of menopause seem to be at more risk for heart attacks, strokes, and breast cancer. Doctors are saying hormone therapy may work in women in the earliest stages of menopause.
The Long and Short of It
- Researchers have discovered that the malfunction of a gene thought to be associated with schizophrenia or depression seems to have symptoms associated with those illnesses. They figured it out thanks to our trusty mice. The mutated gene is called DISC1 (Disrupted in schizophrenia 1).
- Breast-feeding helps new moms battle depression. Consuming foods with omega-3 fatty acids also provides benefits. According to an author named Kathleen Kendall-Tackett, breast-feeding lowers stress levels. However, if the mother is having issues feeding her child, it can have the opposite effect and bring on depression.
- Walter Cronkite’s daughter Kathy has a book, The Edge of Darkness, which details her battle with depression. Oh, and by the way, Joan Rivers and Mike Wallace deal with depression too. (That’s in the book.) EDIT: Polly of polarcoaster.net let me know that Cronkite’s book isn’t new. She was just discussing her experience with depression in Cincinnati’s The Enquirer.
- A new study shows that chronic depression may lead to diabetes in older people.
“The culprit appears to cortisol, a hormone produced in response to stress. When someone is depressed, cortisol levels rise. If depression is chronic, cortisol levels may stay consistently high.” – Debra Manzella, R.N.
Also, make sure you’re working on your 300+ crunches daily:
“Excess belly fat is a known risk factor for diabetes.”
May 1, 2007 at 5:29 pm (Blogs, Mental Health/Illness, Personal, Schizophrenia, Statistics)
Tags: Americans, Archives of General Psychiatry, CATIE, crime, diagnosis, disorder, media, mental health, mental illness, population, psychiatric, psychosis, rampage, Schizophrenia, shooting, study, TAC, Treatment Advocacy Center, USPRA, violence
The subject title is long, but – I think – apropos.
The Treatment Advocacy Center’s post, “A classic case of shooting the messenger,” has been bothering me all day. I’ve been wanting to do further research on their claim that “patients with schizophrenia were 10 times more likely to engage in violent behavior than the general public.” Funny thing is, I didn’t have to look far.
The TAC links to a summary of the CATIE violence study and surprisingly, it contradicts the TAC’s post. I couldn’t help but chuckle once I realized I could easily debunk their claims from what they considered supporting evidence.
USPRA: “Violence is no more prevalent among individuals with mental illness than the general public”
Fact: The CATIE violence study found that patients with schizophrenia were 10 times more likely to engage in violent behavior than the general public (19.1% vs. 2% in the general population).
MY TAKE: “Overall, the amount of violence committed by people with schizophrenia is small, and only 1 percent of the U.S. population has schizophrenia. Of the 1,140 participants in this analysis, 80.9 percent reported no violence, while 3.6 percent reported engaging in serious violence in the past six months. Serious violence was defined as assault resulting in injury, use of a lethal weapon, or sexual assault. During the same period, 15.5 percent of participants reported engaging in minor violence, such as simple assault without injury or weapon. By comparison, about 2 percent of the general population without psychiatric disorder engages in any violent behavior in a one-year period, according to the NIMH-funded Epidemiologic Catchment Area Study.”
This data is a little skewed here. (CLPsych or Philip Dawdy could do a better job at clarifying this for me.) First of all, “about 2 percent of the general population without psychiatric disorder engages in any violent behavior in a one-year period.” How many people does this constitute? The sentence doesn’t specify ‘without schizophrenia’; it says “without psychiatric disorder.” That means Americans who do not suffer at any given time from depression, bipolar disorder, psychosis, anxiety, schizophrenia, obsessive-compulsive disorder, postpartum depression, and the list goes on and on. Can anyone compile complete data of Americans who suffer from a psychiatric disorder? (Why do I have the funny feeling that Americans without psychiatric disorders are becoming the minority?)
In the January 1994 issue of the Archives of General Psychiatry, results of the National Comorbidity Study were released. Diagnoses from the DSM-III were applied to the participants ranging from ages 15-54. The study found that 50 percent of participants reported “one lifetime disorder” and 30 percent said they had “at least one 12-month disorder.”
That was January 1994. The American population has grown significantly since then, so I have a hunch that there's an increase in diagnosing people with psychiatric illnesses. But like I said, that’s, uh, just a hunch. (Keep in mind that the study does not include children ranging from ages 4-14 who are likely to receive ADHD and/or bipolar diagnoses.)
Humor me: Let’s take the NC study’s findings and apply it to the current estimated U.S. population (assuming that the percentage of those with a lifetime disorder has remained the same). Out of nearly 300 million Americans (July ’06 estimate), that means about 150 million Americans have at least some form of a psychiatric disorder. If 1 percent of the general population suffers from schizophrenia, that comes out to 3 million people. If we apply CATIE’s violence percentages, TAC’s right; 19.1 percent of schizophrenic patients engage in violent behavior of any kind. However, the CATIE study also says that two percent of the general population without psychiatric disorder engages in violent behavior. That means out of the remaining 150 million, 2 percent of that would be —*drumroll please* — 3 million Americans! Maybe it’s just me, but doesn’t seem 10 times likely. I could always be wrong.
Read the rest of this entry »
May 1, 2007 at 2:18 pm (Celebrities, Depression, Loose Screws Mental Health News, Mental Health/Illness, PPD, Schizophrenia, Suicide)
Tags: CATIE, Cho, Cho Seung-Hui, cutting, Depression, dissidentvoice.org, mental health, mental illness, postpartum, postpartum depression, PPD, psychosis, Schizophrenia, slit wrists, TAC, Treatment Advocacy Center, violence, Virginia Tech, VT, VTech
I haven’t done this for a while so hopefully I can pick this up again a little more regularly. (crosses fingers)
Read a heart-wrenching story in the UK Daily Mail about a mother whose postpartum depression led her to begin slitting her wrists
Tom Chaplin, singer for the band Keane, has admitted to contemplating suicide.
Tom – who was taking up to two grams of cocaine a day – revealed to Britain’s Q Magazine: “I was at the end of my tether in Japan. I was tired of my life and feeling pretty suicidal. I got off the plane and called my dad. I’d told him that I’d left the band and that I was falling apart. I checked myself into The Priory.”
Chaplin’s interesting view:
Despite his own drugs hell, Tom says it’s a personal decision to experiment with substances. He claims troubled rock star Pete Doherty should be left to take all the drugs he wants.
Tom said: “No-one’s got any right to stop him killing himself.”
An article in the Chicago Tribune on how VNS is beginning to show benefits for some patients. Which reminds me, browse on over to VNSdepression.com to learn more.
Nicholas Vakkur must have read the Treatment Advocacy Center’s post on how the CATIE study shows an increase in violent offenses by mentally ill patients (namely those with psychosis and schizophrenia). He refutes this idea on dissidentvoice.org:
Individuals with a mental illness are far more likely to be the victims, rather than the perpetrators of violence, while the vast majority of people who commit acts of violence against others are not in fact mentally ill.
This rush to stereotype individuals suffering from psychiatric illness as likely murderers is reckless and lacks credulity. Mental illness has no role in the majority of violent crimes committed in our society. Alcohol and substance abuse far outweigh mental illness as factors contributing to violence, while the strongest predictor of violent and/or criminal behavior is a past history of violence and criminality, not a major mental illness.
March 8, 2007 at 1:10 am (Bipolar Disorder, Medicine/Meds, Mental Health/Illness, Pharma)
Tags: affiliations, bipolar, Bipolar Disorder, board, celexa, checklist, citalopram, clinical trials, consultant, Eli Lilly, escitalopram, gabapentin, GlaxoSmithKline, grants, GSK, Havidol, Hirschfeld, imipramine, Lamictal, lamotrigine, Lexapro, MDQ, member, Mood Disorder Questionnaire, paroxetine, Paxil, Pharma, pharmaceutical, pharmaceutical companies, pharmaceutical grants, questionnaire, quetiapine, Robert Hirschfeld, Schizophrenia, Seroquel, sertraline, UTMB, zoloft, Zyprexa
“GlaxoSmithKline, one of the world’s leading research-based pharmaceutical healthcare companies, is committed to improving the quality of human life by enabling people to do more, feel better, and live longer.”
OK, I’ll be honest. I can’t keep up with my own posts and have no idea whether or not I’ve posted on this yet. Judging from the fact that I still have this bp booklet, I’m going to guess not. If I have, then there’s more.
When my psychiatrist diagnosed me with bipolar disorder in November, he handed me a bunch of material: a mood tracker (PDF), an article touting the benefits of Seroquel, and a booklet titled, “Bipolar Disorder,” which refers the reader to www.1on1.health.com.
The booklet seems pretty harmless to a patient newly diagnosed with bipolar disorder:
“Highs and lows can be part of life. But, with bipolar disorder, they can be severe. You may feel too depressed to get out of bed one day. Soon after, you may feel full of energy. You may have normal times between the highs and lows. When people have mood symptoms, it’s more likely to be depression.
Mood swings can be hard to predict. But you may have warning signs. You may even learn what can trigger your symptoms. You’ll read about this and more in this booklet.
Bipolar disorder is complex. Doctors docn’t know what causes it. They know that genes play a role. The illness may be linked to brain chemicals. These chemicals can get out of balance.
There are treatments to help control the symptoms. Learn about your condition. Get help for it. This booklet is a good first step.”
Thank you, GlaxoSmithKline.
GSK, the provider of such psych drugs as Lamictal, Paxil, and Wellbutrin, issues a series of booklets for patients referring them to 1on1health.com. The topics include depression, anxiety disorders, epilepsy, type 2 diabetes mellitus, high cholesterol, among others. The tips seems pretty simple and straightforward:
“Health and lifestyle chances may trigger your symptoms. Some common changes are:
Not having a sleep schedule
Misusing alcohol or drugs
Stopping your medicine, or starting medicine for depression or another illness
Having thyroid or other health problems”
Then it gets into the general stuff about the difference between mania, depression and further clarifies what hypomania and mixed moods are. Then, the kicker follows:
“If you think you may have bipolar disorder, fill out the checklist on the next two pages. Share it with your doctor. He or she can use it to help diagnose you.”
Furious Seasons posted a link about a fake drug named Havidol (which I totally got suckered into because I skimmed the post and missed the “OK, it’s a gag” part), but the hilarity stems from similarly stupid (and vague) questions. I’ve put a screenshot of the PDF GSK provides on their Web site to the right. My issue is not so much with the questions necessarily, but with the lead-in to them:
“Has there been a time when...” [emphasis mine]
It doesn’t matter whether you were 3 years old or 46 years old, if you answered “yes” to more than one “there’s ever been a time when” question, guess what? You MAY qualify for bipolar disorder! A sampling:
Has there ever been a time when…
- You were easily angered that you shouted at people or started fights?
- You felt much more sure of yourself than usual?
- You talked or spoke much faster than usual?
- You were so easily distracted that you couldn’t focus?
- You had much more energy than usual?
- You were much more active or did many more things than usual?
- You were much more social than usual?
- You were much more interested in sex than usual?
Guaranteed everyone reading this said “yes” to at least TWO questions. If not, I question whether you’re breathing. (Sadly enough, this makes me realize how easy it was for me to get fooled by the phony Havidol quiz.)
The follow-up to the questions above asks, “If you checked YES to more than one of the questions above, have several of these things happened during the same period of time?” Then, “How much of a problem did any of these things cause you (like not being able to work, or having money or legal troubles)? Choose one[:]
- No problem
- Minor problem
- Moderate problem
- Serious problem”
The multiple choice question above may not matter. Answering some of the lead-in questions in the affirmative may qualify you for the disorder.
Here’s a nice little tidbit. The questionnaire was “adapted with permission from Robert M.A. Hirschfeld, M.D.” So as an uninformed patient reading this (which I was at the time), I’m thinking, “Oh, this must be legit since they got permission from a doctor to use this checklist.” There’s more than meets the eye here.
On the surface, Dr. Hirschfeld seems like an awesome doctor – and he very well may be. Dr Hirschfeld’s bio from the University of Texas Medical Branch at Galveston (UTMB) extols the “Professor and Chair” of its psychiatry deparment. He has history of working with various national organizations such as the National Depressive and Manic-Depressive Association, National Institute of Mental Health (NIMH), and National Alliance for Research on Schizophrenia and Depression (NARSAD). He’s written all kinds of articles and blah blah blah. He’s considered a leader in his research of bipolar disorder.
In fact, because Dr. Hirschfeld is so great, he’s a member of pharmaceutical boards and has acted as a consultant for pharmaceutical companies, according to ISI Highly Cited.com. Some of our favorite guys appear here: Pfizer, Wyeth, Abbott Labs., Bristol-Myers Squibb, Eli Lilly, Forest Labs, Janssen, and – lookee here! – GSK.
The duration of Dr. Hirschfeld’s affiliations with these pharmaceutical companies are unspecified. All other “appointments/affiliations” have assigned years, i.e. 1972-1977, 2001-Present. His consulting affiliations follow his internship in 1968-1969. It looks a bit misleading to follow the consulting jobs after, oh say, 1969, and not provide dates of when he became a consultant for all of these pharma companies. Toward the end of the document that I found, his affiliations from 1986-Present are listed with various boards, associations, journals, and a slew of pharmaceutical companies.
Hello, hello, hello. He is a MEMBER of the Zyprexa U.S. Bipolar Academic Advisory Board, the Celexa/Excitalopram [sic] Executive Advisory Board, the Lamictal National Advisory Board, and the Zoloft Advisory Board.
Humor me here. His clinical trials include:
- 1994 Paroxetine for Dysthymia (SmithKline Beecham)
- 1995-97 Several (I found five) double-blind studies on sertraline and imipramine in patients qualifying for the DSM-III definition of major depressive disorder
- 1996-98 Gabapentin therapy for bipolar patients
And the list, including mirtazapine, fluoxetine, venlafaxine, lamotrigine, goes on. You can also find the “grants” pharma companies gave to fund these clinical trials.
From 1997-2000, Hirschfeld received a $100K grant from Abbott Labs to develop “a new checklist for bipolar symptoms.” (I’m not sure what the old one was.) In 2001, he received a $142K grant for the “Bipolar Prevalence and Impact MDQ Project.”
I don’t even need to look MDQ up. It’s Mood Disorder Questionnaire. The grant came from GSK, who “adapted” the questionnaire with Hirschfeld’s “permission.” That sounds simply gravy.
To understand more about bipolar disorder, you can listen to the stories of Greg, Stuart and Leslie – all your classic bipolar cases and how medication and/or therapy has helped them so much. You can also watch the bipolar
disorder animation that regurgitates all the things that we’ve become skeptical about.
In the meantime, remember the instructions included in Seroquel’s safety information that no one reads (excuse the crappy “Paint” job):
March 3, 2007 at 1:25 am (Antidepressants, Antipsychotics, Bipolar Disorder, Medicine/Meds, Pharma, Schizophrenia)
Tags: anxiety, bifeprunox, bipolar, Bipolar Disorder, clinical trials, Depression, desvenlafaxine, diabetic, Effexor, Effexor XR, fibromyalgia, GAD, Generalized Anxiety Disorder, hot flashes, learn and confirm, levonorgestrel, lybex, MDD, menopause, neuropathic apin, PMDD, premenstrual dysmorphic diroder, Pristiq, Schizophrenia, vasomotor symptoms, venlafaxine, Wyeth
News stories on Wyeth’s Pristiq, Effexor’s “knockoff”, have focused on the drug’s uses that are pending FDA-approval: vasomotor symptoms accompanying menopause (see hot flashes) and depression. (“Knockoff” term courtesy of CLPsych.) The major media has failed to pick up on Wyeth’s Phase III clinical trials to use Pristiq for fibromyalgia and neuropathic pain (injured tissue or damaged nerve fibers) in diabetics. A search for Pristiq on Wyeth’s Web site yields no results. Desvenlafaxine yields two very meager results.
In related matters, bifeprunox is pending FDA-approval for the use of schizophrenia and is still in Phase III for use of bipolar disorder. They are also in Phase III of testing Lybrex (levonorgestrel) for use for Premenstrual Dysmorphic Disorder in addition to the drug functioning as an oral contraceptive. (I’ll be honest; I had NO clue that diagnosis existed.) In any event, I’ve been misdiagnosed because according to the symptoms, I qualify. I think I also qualify for OOPS – Overdiagnosed and Overmedicated Patient Syndrome.
I’d like expound on Wyeth’s Learn and Confirm phase that’s supposed to replace Phase I and II of clinical trials. It sounds like a speedier way to just get drugs to Phase III of clin. trials, but it’s late and I’m working on something else, so I’ll save that for another day.
Also something to tackle in the future: All these interesting clinical trial results for Effexor XR involving depression and GAD. We’ll see…
digg it | reddit | del.icio.us
March 2, 2007 at 11:49 am (Antipsychotics, Medicine/Meds, Pharma)
Tags: AstraZeneca, bipolar, Decision Resources, Eli Lilly, gold standard, Lamictal, lamotrigine, meds, Olanzapine, PR, psych meds, psychosis, quetiapine, Schizophrenia, Seroquel, Zyprexa
Whee for self-promotion!
“Eli Lilly’s Zyprexa Will Remain the Clinical Gold Standard for the Treatment of Schizophrenia Through 2015”
“Clinical Gold Standard,” huh?
I can’t bring anything new to the table on this. Maybe I’m wrong, but here I go:
“For almost three decades, Decision Resources has provided in-depth research on the trends, emerging developments, and market potential in various healthcare industry sectors. Our client base is diverse – including large pharmaceutical companies, emerging biotechnology concerns, financial services, managed care organizations, and medical device manufacturers who turn to Decision Resources to help shape their strategy and master their chosen markets.
The privately-owned company offers a rich array of research publications advisory services, and consulting that make it second to none for quality, analytical depth and insight. With access to almost 10,000 thought leaders, specialists, HMO formulary directors, and general practitioners, Decision Resources’ highly-credentialed analysts are able to reconcile real-world practice with hard numbers from the industry’s most respected data sources. The resulting analysis and insights drive business decisions and commercial success within the biopharmaceutical, managed care, medical device, and financial markets.”
Here’s my assessment, take it with a grain of salt: In an attempt to fight the decline in sales from the NYT-induced Zyprexa backlash, Eli Lilly has gone on the offensive and hired Decision Resources to reinvent its star medication.
Decision Resources (DR), a privately owned company (no hyphen if a modifier ends in “-ly”), has a client base that includes large pharmaceutical companies. Ta-da! Don’t get it?
Decision Resources is not a public company; hence, in addition to not receiving federal money, it doesn’t need to report its financial dealings to the SEC. Therefore, no publicly accessible financial records of DR’s clients. They haven’t said they are an “independent” organization. Perhaps this is implied. Whatever the case may be, DR gets paid by its client base to research their products and “help shape their strategy and master their chosen markets.”
This isn’t brain science; this is on their “About Us” section of their Web site. Therefore, if Eli Lilly turns to DR and pays them to – I like DR’s wording here – “shape their strategy and master their chosen markets,” then DR is essentially a PR loudspeaker letting everyone know that Zyprexa is the “clinical gold standard” for schizophrenia.
What a bunch of hooey.
Not too long ago, it seems that AstraZeneca (AZ) may have had DR engineer its new marketing strategy to give Seroquel a boost. Why not? Mental health media watchdogs are hatin’ on the atypical antipsychotics.
“According to a new report entitled Schizophrenia: Turning Physician Insight into Projected Patient Share, Zyprexa is superior in efficacy to all other current therapies, particularly on measures that are most important to prescribers, such as impact on global symptoms and responder rate.”
Holla at me if you’ve got your hands on that report mentioned above.
“In spite of scoring* less favorable than the other drugs in terms of safety and lower than risperidone in terms of delivery features, Zyprexa is the gold standard.”
OK – so it’s not safe and it doesn’t deliver as well as Risperdal – whatever that means – but Zyprexa is still “the gold standard”?
“This overall advantage for a drug with significant safety concerns highlights the importance of efficacy to prescribers.”
I want you to reread that: ” This overall advantage for a drug with significant safety concerns highlights the importance of efficacy to prescribers.” Let’s attempt to paraphrase this: The benefit of this potentially harmful drug shows the importance of how effective it is to those who receive the drug. Although Zyprexa has “significant safety concerns,” the drug works well enough for doctors to prescribe it to patients. Uh, no. Positives don’t outweigh the negatives. It was nice jargon for a second there, though. (If this is effed up enough for adults, why subject children to this crap?)
“The report also finds that the most commercially important emerging antipsychotics (Janssen’s Invega, Organon BioSciences’ asenapine, and Wyeth/Solvay/Lundbeck’s bifeprunox) score* lower than Zyprexa, indicating that Zyprexa will remain unsurpassed during Decision Resources’ forecast period.”
I know I’m doing a play-by-play but this is important. I need to find out how DR decided that Zyprexa would be the “gold standard” until 2015. (
What’s the significance of this year? Does EL’s patent on Zyprexa expire then? Nope, Eli Lilly’s patent on Zyprexa expires in 2011. Expect a similar molecularly structured olanzapine before then. Biolexapine?) So basically, in this report, DR’s conclusion is Zyprexa beats every other atypical antipsychotic for schizophrenia by far. Notice that AZ’s Seroquel (the soon-to-be “gold standard” of bipolar meds), an atypical also used for schizophrenia, is not listed. Not coincidence.
The little asterisk (*) next to the word “score” prompts me to wonder: Just how did they come up with these scores? Well, the asterisk tells me that I need to contact DR for the methodology behind the product scores. I just might. Then send it off to CL Psych or Furious Seasons to decipher the crap out of it.
Another thing to note on this PR:
“”Invega is a metabolite of risperidone and is likely to have efficacy similar to that of risperidone, which scored* slightly lower than Zyprexa overall,” said Nitasha Manchanda, Ph.D., analyst at Decision Resources. “Asenapine also lacks the differentiation to replace Zyprexa as the gold standard because it does not make as significant an impact on global symptoms, and bifeprunox is significantly inferior to Zyprexa in all primary efficacy measures and is not capable of surpassing Zyprexa.””
Dr. Manchanda, analyst for DR, pulled bifeprunox – not yet on the drug market – into the Zyprexa comparison and somehow was able to call it “significantly inferior to Zyprexa” with an incapability to “surpass” it. How many people have used bifeprunox, Ms. Manchanda? OK, now tell me how many people have used Zyprexa? And you’re telling me that a drug that hasn’t yet hit the market is “significantly inferior” to a drug that has been on the market for the past couple of years and has 1,200 lawsuits still pending in addition to the millions that have already been paid?
As for AZ, DR has determined that Seroquel will become the “gold standard” for bipolar medication by 2010, knocking Lamictal out of its current “gold standard” status. Like Furious Seasons, I had NO idea Lamictal was held up so highly for bipolar meds. Considering that lithium has always been the king of bipolar meds and treats both acute mania and depression better than Lamictal, I’m surprised to read this.
“According to the new DecisionBase report entitled Bipolar Depression: Turning Physician Insight into Projected Market Share, Seroquel’s advantages over Lamictal include the more profound effect on depressive symptoms seen in short-term trials.”
My doctor precribed Lamictal to me for management of depressive symptoms in bipolar disorder. He conversely prescribed Seroquel for mania (and to help me get sleep). Getting back to the short-term trials, Lamictal was tested for 18 months for long-term management of bipolar disorder. Seroquel, however, was tested for 8 weeks. Effective for the short-term? Perhaps. But most patients on atypicals take them long-term. And that’s precisely where Seroquel fails.
“The drug’s efficacy on this measure differentiates it from other therapies, according to thought-leading psychiatrists, and the importance assigned to this measure by prescribing psychiatrists drives Seroquel’s product score above Lamictal’s.*”
According to thought-leading psychiatrists who probably function as consultants and analysts for “large pharmaceutical companies.” Seroquel may have the potential to sell more than Lamictal by 2010 – if this is what DR’s gauging. However, it seems like DR is trying to push Seroquel, not just as a better market share, but as a better product. In this “report,” DR also fails to compare Seroquel’s efficacy to Zyprexa’s. What a convenient absence for a product used for psychosis in bipolar disorder.
(ignore any spelling errors in this post. it’s late and i bumped my forehead against the edge of a car door in the rain. ouch.)
January 29, 2007 at 2:12 pm (Antidepressants, Bipolar Disorder, Depression, Loose Screws Mental Health News, Medicine/Meds, Schizophrenia, Suicide)
Tags: Depression, Disco D, faces, genes, genetic, Germany, police homicide, psych meds, Schizophrenia, Scientologists, Scientology, suicidal thoughts, Suicide
As much as I hate to admit it, the Scientologists have a point.
A group linked to Scientology staged a protest near a school after a student on psychiatric drugs stabbed a classmate to death. The point of the protest was to highlight “the dangers of antidepressants.”
“Several Scientologists held signs that mentioned by name John Odgren, the teen accused in the fatal stabbing. Signs included slogans such as “What psychiatric drugs was John Odgren prescribed?” and “Stop combining drugs to make walking time bombs.”
Odgren, 16, has been diagnosed with Asperger’s syndrome, a mild form of autism, and according to his attorney was taking several prescription medications at the time of the stabbing. Odgren lived in Princeton but attended a special education program at L-S.”
I didn’t know that psychiatric drugs made people homicidal. I guess if they can make people suicidal then homicidal isn’t that far off.
“’There’s a lot of concern around the country when kids are becoming violent on psychiatric drugs,’ said Kevin Hall, the Scientology group’s New England director.”
Concern from who? This is probably something I should look into. See my favorite quote below:
“This is not a serious request by a serious group,” said School Committee Chairman Mark Collins on the demand that Odgren’s medical records be made public.”
Ouch. Scientology dismissed in one sentence.
UPDATE: Psychiatry drugs supposedly have no violent effect on children. But there are two sides to the debate.
Version 1 —
“Though the Food and Drug Administration currently includes a warning, called a ‘black box warning,’ on SSRIs stating studies have shown increased risk of suicide, particularly among teens and children, [John Fromson, chair of the psychiatry department at MetroWest Medical Center] said there are no studies which show the drugs cause violence toward others.
‘Violence is a social issue here,’ he said. ‘Illicit street drugs can do that…but to make a connection between medication that’s prescribed for legitimate reasons and at appropriate doses and violence – the scientific evidence just isn’t there.'” [emphasis mine]
Version 2 —
“Advocates like Lisa Van Syckel, however, insist the drugs can lead to violence, because they’ve seen it firsthand.
Van Syckel’s anti-depressant ordeal began seven years ago, when her then- 15-year-old daughter Michelle was prescribed the SSRI Paxil for depression and anorexia.
Over the next year, Van Syckel said, she attacked her brother, she viciously attacked three police officers, she went after another student with a baseball bat and she cut the word ‘die’ into her abdomen.
After nearly a year on the medication, doctors changed Michelle’s diagnosis to Lyme disease, and gradually weaned the teen off the drugs, and Van Syckel said Michelle has been herself ever since.”
Perhaps the scientific evidence isn’t there because clinical studies don’t track adolescents long enough to determine whether a propensity toward violence to others significantly increases.
A Mexican man who tried to commit suicide became a victim of police homicide. (Weird.) He threw himself on the train tracks in the Mexico City subway and was eventually rescued by station employees. After two policemen took him into custody, they allegedly beat him to death inside their patrol car. It’s so sad that this man had a second chance at life and two stupid policemen took it away.
I didn’t know this was possible:
“A 23-year-old man who sold a lethal cocktail of drugs as “suicide pills” on the Internet was sentenced by a court in Germany on Wednesday to three years and nine months in prison. The man pleaded guilty to 16 counts of the illegal sale of pharmaceuticals, a spokesman for the court in Wuppertal said.”
Wow. Who does a Google search for “suicide cocktail” or “lethal drug cocktails”? Isn’t it easier (and cheaper) to do it the old-fashioned ways: crash a car, hanging, jumping off a bridge…? Not advocating suicide, but I don’t understand why people need to pay for suicide. Maybe they’re wussies like me. But that’s what overdosing on pills is for. The Captain Obvious quote of the day:
“Suicide and assisting suicide are not illegal in Germany.”
Maybe I should move to Germany. (KIDDING. Just kidding. Sort of.)
50 Cent’s producer Disco D (Dave Shayman) killed himself on January 23. Although not much is known about his death, there is speculation that Disco D had bipolar disorder.
“DJ Vlad, a good friend of D, was shocked upon hearing the news.
‘Disco D was a good friend of mine. I lived with him in Brazil for a couple weeks. He was a real artist,’ Vlad revealed. ‘I just talked to him a few days ago, and he told me things were hard. I tried to cheer him up. I didn’t realize how hard it really was. I’m devastated right now.’”
No one really knows how difficult it is for someone struggling with depression and suicidal thoughts unless you’ve been there.
An article from IHT details interesting research that Harvard’s McLean Hospital is conducting to find out more about genetic schizophrenia.
“Consider, said Deborah Levy, the lab’s director: ‘The incidence of schizophrenia is stable at about 1 percent, and schizophrenics have very low reproductive rates. So what is keeping those genes going? One hypothesis is that most of the people carrying the schizophrenia genes are not the patients. Rather, they are some of the well parents and well siblings, most of whom never show signs of the illness.’”
Hmm. Is that why I’m an only child?
“The effects of such genes may show up in a variety of subtle ways, they say – including faulty eye-tracking and asymmetry in facial features so hard to detect that it is best measured by highly specialized 3-D cameras.
At Levy’s lab, people with schizophrenia and their relatives undergo 10 to 12 hours of tests. … The faces are measured in minute detail by Curtis Deutsch, a genetics expert who focuses on facial variations and their links to various diseases. … So, subtle abnormalities in the shape and layout of a face may reflect specific abnormalities in brain structure, he said. Thus far, he said, he has found that some schizophrenics do have certain minor facial anomalies – none of them visible to the naked eye – as do some of their healthy relatives.”
So it’s possible that facial features and movements could provide a clue to schizophrenic genes or perhaps increased risk for schizophrenia. The article’s pretty interesting. Go read the rest of it.
January 29, 2007 at 12:45 pm (Mental Health/Illness, Personal)
Tags: Africa, Africans, ancestors, bipolar, Bipolar Disorder, blacks, Caucasians, clinical jargon, DeGruy-Leary, diagnosis, doctors, Dr. Joy De-Gruy-Leary, DSM-IV, DSM-IV TR, ethnic background, ethnic group, ethnic imbalance, Europeans, Fasuyi, mental health, mental health system, mental illness, Morenike Fasuyi, NIMH, patient responsibility, patients, physicians, Post-Traumatic Slave Syndrome, post-traumatic stress disorder, PTSD, PTSS, race, racism, Schizophrenia, UK, United Kingdom, whites
Liz Spikol linked to this article back in December and as a Black American with West Indian heritage (and by default, African and French), I couldn’t resist commenting.
Author Morenike Fasuyi blasts the United Kingdom’s mental health system as being less than inadequate for Africans. I don’t doubt it.
I do wonder about Fasuyi’s seemingly sheer hatred for anyone of European descent (in America, we’d refer to them as “white” or “Caucasian”). The article seethes with anger.
“The general consensus suggests that African people have to work twice as hard as their european counterparts in every aspect of our social, cultural and economical existence in order to make ends meet.”
This also is the case for Black Americans.
Fasuyi explains how she’s been diagnosed with bipolar disorder but says her disorder is mainly triggered by things related to Africa: “slavery, politics, oppression.” Her turning point was on May 1, 2004 when “it was as if [her] ancestors called” upon her and “removed the scales from her eyes.” She refers to Karl Marx when speaking about “groups” – Africans – who are oppressed and eventually rise up and lead a revolution. In addition, she believes the numbers 7 and 9 relate to the African people and that 2007 could be the year when “division within the African community” would be “homogenized[d]… to effect change.”
As a Black American, I know that African people truly value their ancestors and even practice ancestry worship. This is where I believe she is coming from. To any other nationality, Fasuyi is crazy (no pun intended). It wouldn’t surprise me if her mental health status file read, “bipolar disorder with psychosis.” Not knowing about African ancestry worship can make any doctor of non-African nationality misdiagnose Fasuyi. To be able to accurately help her, she must be accurately understood.
She asked for an African psychiatrist who might have a cultural understanding of where she was coming from. She mentions this was a slow process since “there [were] hardly any.” She also asked for an African social worker but was given “an insensitive male european (sic) social worker who adversely affected my health with his actions, racist remarks and incompetence.”
She takes a nice jab at Big Pharma and pharma reps, too:
“Maintaining you within the system keeps consultants in their jobs and increases the profit of the pharmaceutical industry, which has a turnover of billions.”
Zyprexa; Cymbalta, anyone?
Read the rest of this entry »
January 24, 2007 at 2:00 pm (Antipsychotics, Medicine/Meds, Pharma)
Tags: Bloomberg, Byetta, chart, diabetes, drug companies, drugmakers, Eli Lilly, exenatide, medication, Metro, Metro newspaper, Metro Philly, Olanzapine, Pharma, pharmaceuticals, psych meds, Schizophrenia, Zyprexa
I found this Bloomberg chart in the Metro Philly newspaper and thought it showed an interesting paradox. I tried to find a link for it on the Internet but as of yesterday, there was none.
January 23, 2007 at 12:59 pm (Antipsychotics, Depression, Loose Screws Mental Health News, Medicine/Meds, Mental Health/Illness, Military, Schizophrenia, Suicide)
Tags: Ambien, Army, atypical antipsychotic, atypicals, biomarker, child abuse, coughing, depressed, Depression, Editor and Publisher, Furious Seasons, IPS News, mental illness, Military, Pentagon, pharmaceuticals, PPI, prepulse inhibition, psych meds, psychiatric, psychiatric disorder, psychological, psychotropic meds, psychotropics, PTSD, Qanapin, quetiapine, remission, Schizophrenia, Seroquel, soldiers, Stars and Stripes, startle response, stress disorder, Suicide, suicides, troops, typical antipsychotics, typicals, VA, veterans
According to a press release (I’m well aware what I’m saying), a recent study possibly shows that schizophrenia’s physical effects are more widespread in the body; researchers previously theorized that schizophrenia was limited to the central nervous system.
“The findings could lead to better diagnostic testing for the disease and could help explain why those afflicted with it are more prone to type II diabetes, cardiovascular diseases, and other chronic health problems.”
Apparently, those who suffer from schizophrenia have abnormal proteins in the liver and red blood cells. While schizophrenia’s most visible effects are psychological, researchers have noted that schizophrenics are at a higher risk for “chronic diseases.” The genetic and physical implications of such a study could prove interesting, especially for those suffering from and at risk for schizophrenia. Also in schizophrenia news, researchers have noticed an “excessive startle response.” The startle response, known as prepulse inhibition (PPI), is being considered as a biomarker for the illness.
Something Furious Seasons might like to argue if he hasn’t taken the following on:
“Lastly, but quite importantly, atypical antipsychotic were found to be more effective than typical antipsychotics in improving PPI, thus ‘normalizing’ the startle response. This led the authors to note:
‘Because an overwhelming number of patients with schizophrenia are currently treated with atypical APs, it is possible that PPI deficits in this population are a vanishing biomarker.”
What’s the advantage with atypicals vs. typicals? How do they work differently? *sigh* I need a pharmaceutical-specific wikipedia.
Schizophrenia News previously wrote about how proof is lacking in schizophrenia developing in those who have suffered from child abuse. (Excuse me for the awful construction of that sentence.) However, a new study shows that those at a high risk for schizophrenia benefit from having a good relationship with their parents during childhood. Read more.
Editor and Publisher has noted that suicides among Army soldiers doubled in 2005 compared to 2004.
Read the rest of this entry »
January 22, 2007 at 4:19 pm (Antipsychotics, Medicine/Meds, Mental Health/Illness, Schizophrenia)
Tags: antypical antipsychotic, atypicals, bifeprunox, dopamine, medication, psych meds, psychosis, Schizophrenia, Wyeth
Someone get this on Furious Seasons’ radar:
Wyeth is also in development for an atypical antipsychotic, bifeprunox, for schizophrenia. Bifeprunox has no trade name yet.
“Bifeprunox, a dopamine partial agonist, is an investigational atypical antipsychotic for the treatment of schizophrenia. Clinical data were presented from safety and efficacy studies that evaluated bifeprunox for the treatment of schizophrenia in both acutely psychotic patients and patients who have stabilized disease.
While bifeprunox has been shown to have a smaller mean effect in acute psychosis when compared with older atypical antipsychotics that have some well-known side effects, it may be particularly well-suited for patients who are experiencing side effects with their current therapy. The safety data for bifeprunox have consistently shown a favorable weight and metabolic profile in both short- and long-term studies, which is a common and serious side effect that can cause patients to stop taking their medication.”
A few questions on Wyeth’s schizo drug:
- How long before this is marketed to bipolar I’s with psychosis?
- Older atypical antipsychotics or older typical antipsychotics?
- I’d like to see the data on weight and metabolic profiles on this. Most APs don’t have a good track record with weight, i.e. Seroquel, Abilify, Zyprexa.
Bifeprunox will developing over the coming months and years. I’ll probably check out clinicaltrials.gov in the future to check on updates.
January 12, 2007 at 9:04 am (Children, Depression, Loose Screws Mental Health News, Mental Health/Illness, Schizophrenia, Suicide)
Tags: abuse, American Academy of Neurology, Archives of General Psychiatry, biopharmaceutical company, bipolar, Bipolar Disorder, business wire, child abuse, CPAP, depressed, Depression, funding, headaches, loose screws, manic-depressive, MDD, mental health, mental illness, mental illness news, migraines, neglect, News, News 24, nightmares, non-profit, non-profit organization, Omeros, Omeros Corporation, pharma company, physical abuse, PTSD, relaxation, researchers, Schizophrenia, sleep apnea, sleep disturbances, sleep problems, SMRI, Spikol, Stanley Medical Research Institute, studies, study, suicidal, suicidal ideation, Suicide, Suicide attempts, Trouble With Spikol, UPI, yoga
I need a new subject header for “Mental health news.” It’s so blah. I need something snazzy. Perhaps “Loose Screws News”? Okay, nevermind… That’s what I get for being a former copy editor. Renamed as of 2/16/2009.
A new study, published in the scientific journal of the American Academy of Neurology has found that women who experience chronic headaches, namely migraines, are four times as likely to report symptoms of major depressive disorder. Of the 1,000 women surveyed, “593 reported episodic headache (fewer than 15 headaches per month) and 439 had chronic headache (more than 15 headaches per month).” Migraines were diagnosed in 90 percent of the women. Author of the study Dr. Gretchen Tietjen said that more studies are being done to discover whether the a serotonin imbalance in the central nervous system is the cause of chronic headaches, severe physical problems, and major depressive disorder. (source: The Trouble With Spikol)
According to businesswire.com, the non-profit organization Stanley Medical Research Institute (SMRI) will provide up to $9 million to fund Omeros Corporation’s schizophrenia program, which will help the completion of
Phase 1 clinical trials. Business Wire basically listed SMRI’s press release so I’m curious to do some research on SMRI and how this non-profit was able to obtain $9 million. I don’t know much about this organization but a non-profit organization funding a biopharmaceutical company’s program seems out of the ordinary to me. (This may be something normal, but I’m not aware of this.) According to SMRI’s “about us” blurb at the bottom of the PR, they state:
“The Stanley Medical Research Institute (SMRI) is a nonprofit organization that supports research on the causes and treatment of schizophrenia and bipolar disorder (manic-depressive illness), both through work carried out in its own laboratories and through support of researchers worldwide who are working on these diseases. SMRI has provided over $200 million in funding since 1989.”
Whoa. $200 million since 1989 is not a whole lot. Where in the world did this $9 million come from? Do non-profit organizations actually save up money to blow on a worthy future project? (The cynical patient in me wonders if there’s a drug company like GSK or Wyeth slipping money through SMRI’s back door.)
Liz Spikol usually blogs headlines before I can even get to ‘em so I credit her with discovering the following three links:
According to the Delhi Newsline, yoga can help with cases of severe depression and schizophrenia. (Hm, interesting.) Patients who took yoga classes in addition to meds improved more rapidly than patients only on meds. The connection with yoga seems to be the relaxation component — outdoing counseling and “talk therapy,” which can aid treatment in a mentally ill individual.
Oy. UPI has reported that Swedish researchers have discovered that those who struggle with suicidal ideation have problems with nightmares and sleep problems. Of the 165 patients surveyed, 89 percent of them reported a sleep problem. Nightmares proved to be the highest indicators of those with a high suicide risk. However, lead author Nisse Sjostrom is quick to note,
“Our finding of an association between nightmares and suicidality does not imply causality.”
“Our findings should inspire clinicians to include questions concerning sleep disturbance and especially nightmares in the clinical assessment of suicidal patients.”
My husband thinks I suffer from sleep apnea – he claims I stop breathing sometimes in the middle of the night. I’m going for a sleep assessment sometime in February so I’ll let you know if I come back with a CPAP (continuous positive airway pressure) machine.
I’ve had increased dreams (or nightmares, what have you) on these psych meds. I haven’t been excessively suicidal and I hope it’s no indication of more suicide attempts on the way. *sigh* Were any of the surveyed patients on meds like Effexor and Lamictal?
(ASIDE: Dang working in a medical industry! I’m becoming more familiar with unfamiliar medical acronyms.)
And finally, News 24 reports that children who suffered from neglect and abuse are more likely to develop severe depression as adults. The study, published in the Archives of General Psychiatry, says the data specifically shows that “depression is a consequence of… abuse.” Um, who wouldn’t be depressed after such a traumatic experience? How do physicians differentiate between major depressive disorder (DSM-IV term for clinical depression) and post-traumatic stress disorder? Ah, once we get the answer, we can use it as a Jeopardy! question.
January 5, 2007 at 8:19 am (Antipsychotics, Medicine/Meds, Mental Health/Illness, News, Pharma)
Tags: Alex Berenson, Berenson, bipolar, Bipolar Disorder, death, diabetes, drug, Eli Lilly, heart disease, hyperglycemia, Kauffman, Lilly, medication, meds, mental health, mental illness, mentally ill, New York Times, NYT, obesity, Olanzapine, psych meds, psychosis, Schizophrenia, settlement, weight gain
More on Zyprexa, folks. It just isn't going to go away.
NYT reporter Alex Berenson, continuing his stellar coverage of Zyprexa's risks and exposing Eli Lilly's deceitfulness, has uncovered a recent case of a man who died using Zyprexa. John Eric Kauffman has a complicated medical, which might have led to his death. However, he was a mentally ill patient on Zyprexa and as a result of his death, Eli Lilly must report his death to "federal regulators," which it is required to do under law. However, despite his heavy smoking, he gained 80 lbs. on Zyprexa – which possibly led him to develop heart disease and become sedentary after being active most of his life. His mother says that Zyprexa did help him stave off the psychosis of his bipolar disorder, but his mother wonders if the risk was worth the early death of her son. Kauffman at 41 years old weighed 259 lbs. at the time of his death. He was 5' 10".
Which leads to the question of whether mentally ill patients should choose between taking Zyprexa – which CAN help mentally ill people – and dealing with its significant side effects or risk not taking Zyprexa when other medications won't work. In light of all this, should a doctor even continue to prescribe Zyprexa after seeing its awful side effects but left with no other choice (given that a patient is treatment-resistant to most medications)?
Eli Lilly's response to this continues to be appalling:
"Zyprexa is a lifesaving drug and it has helped millions of people worldwide with schizophrenia and bipolar disorder regain control of their lives."
It may be true that it helps people "regain control of their lives," but as for being a lifesaving drug – that's unlikely. Zyprexa has been shown to induce diabetes, obesity, hyperglycemia, and now, heart disease and death. I commend Australian regulators for looking into the details of Lilly downplaying the risk of Zyprexa and hope that they will make the information public – a different course than what the U.S. federal government seems to be taking. Lilly's 2006 settlement with patients who developed diabetes and other health problems is pure evidence that despite their constant denials, Lilly's hiding something in an effort to make profits.
My prediction: The FDA will eventually slap a black-box warning on Zyprexa, warning patients that it makes them more prone to diabetes and its other ill health effects.
January 4, 2007 at 11:02 pm (Bipolar Disorder, Depression, Mental Health/Illness, Schizophrenia)
Tags: Antipsychotics, bipolar, Bipolar Disorder, bipolar I, bipolar type, breakfast symposium, CATIE, clinical trial, compensation, free, genetics, genetics study, meds, schizo-affective, schizo-affective disorder, Schizophrenia, study, symposium, UPenn
I don’t know much about the CATIE study (haven’t researched it yet) but feel free to go to the FREE CATIE breakfast symposium near you.
From the site:
At the end of these educational activities, participants should be able to:
- Differentiate the clinical outcomes among patients prescribed the various treatment modalities in the CATIE study.
- Choose an efficacious medication that improves symptoms in patients with schizophrenia who have failed on previous treatments.
- Choose a tolerable medication to improve compliance in patients with schizophrenia who have discontinued previous treatments.
- Individualize treatment for patients with schizophrenia based on history of symptoms, ability to tolerate adverse effects, and comorbid illnesses.
- Discuss the effectiveness of antipsychotic medications for schizophrenia in terms of efficacy, tolerability, and cost.
I’ve heard about the CATIE study from sites like Furious Seasons and Clinical Psychology and Psychiatry, but now that I know it deals with schizophrenia, I’m interested in learning more about it.
In other news, I attended a Bipolar and Depression Support Group tonight and received a presentation from UPenn on a genetics study they are doing to study bipolar disorder. They need 4,000 volunteers with bipolar disorder to help and they currently only have 2,000. If a person qualifies for the study, he or she will receive a $100 compensation. The study closes in December 2007. The following is some more information:
- Individuals 16 and older with Bipolar I Disorder or Schizo-affective Diorder, Bipolar Type, are eligible to join this study.
- Participation involves the following:
- Completion of questions
- A 1-2 hour interview (in person or over the phone)
- Small blood sample (drawn at UPenn’s expense)
- $100 compensation
- The study does not change your treatment.
- No travel required.
I can’t stress enough that people will bipolar disorder should participate in the study. Again, people do NOT need to live in the Philadelphia or Pennsylvania area to participate. People with bipolar disorder who live ANYWHERE in the United States can participate in the study. Please, let’s help make this study a success to improve treatment – not only for ourselves but also for future generations.
January 2, 2007 at 4:21 pm (Medicine/Meds, Mental Health/Illness, Personal, Pharma)
Tags: Dawdy, diabetics, disclosure, discrimination, Furious Seasons, health disclosure, job, mental health, mental illness, New York Times, NYT, Philip Dawdy, Schizophrenia, seattle weekly
Furious Seasons linked to this article about an internist who forgot about an incident with an Eli Lilly rep — until recently. Great excerpts:
"I was reminded of the incident last week when news reports emerged that Eli Lilly had reportedly urged primary care doctors to use the drug for elderly patients with symptoms of dementia. The company has denied promoting the drug for off-label uses.
The reports highlighted for me the crucial role that internists and other primary care doctors play in screening for psychiatric illnesses but also in knowing when to refer these patients for proper treatment. Although psychiatrists are not always available and not all patients are willing to see them, doctors must carve out our areas of expertise in keeping with our training and experience, and depression and psychosis are simply not my areas as an internist.
I tell [patients] that this cost-benefit decision [of prescribing medicines] should be made in conjunction with the patient's psychiatrist, not solely by an internist placed under pressure by a salesperson."
To read this article, you must register with the LA Times' Web site. If you don't want to do that, just type in the following to get to the article:
Read the rest of this entry »
December 24, 2006 at 10:10 pm (Antidepressants, Antipsychotics, Children, Loose Screws Mental Health News, Pharma, Suicide)
Tags: atypical, big pharma, Furious Seasons, GlaxoSmithKline, GSK, Invega, J&J, Johnson & Johnson, NAMI, Newsday, paliperidone, paroxetine, Paxil, Paxil CR, ping, Risperdal, Risperidone, Schizophrenia
NAMI is touting a new atypical… in the press release for Johnson & Johnson. Michael J. Fitzpatrick, executive director of NAMI lent a statement in J&J’s pr about Risperdal’s sibling, Invega. *sniff, sniff* Something smells fishy about this. Makes me wonder if these non-profits bag money from Big Pharma under the table… (source: Furious Seasons)
An electronic ping sent from Sprint to the police helped save the life of a college student who tried to commit suicide, according to Newsday. A ping also helped save the lives of James Kim’s wife and children after getting stuck in the mountains of Oregon. This ping thing is interesting. Especially since Newsday needs to put quotes around it because ping isn’t a real vocabulary word… yet.
Merry Christmas to all and to all a good night.
ADDENDUM: Oooh, ooh, ooh – just found out: Any family that has a minor who may have consumed Paxil or Paxil CR is eligible for a stake in a $63.8 million settlement with GlaxoSmithKline. More info about the settlement at paxilpediatricsettlement.com. Apparently, it seems as though GSK covered up information about the medications’ safety and efficacy. This is one I’d like to learn more about considering I’ve been on Paxil. Not as a minor but the settlement raises questions regarding GSK withholding information about Paxil’s safety and efficacy regarding adults.
Is it now fashionable to sue pharma companies for not making all of their information public?
December 18, 2006 at 1:44 pm (Depression, Medicine/Meds, Mental Health/Illness, News, Personal, Pharma)
Tags: bipolar, Bipolar Disorder, celexa, dementia, Depression, dosage, drug reps, Effexor, Effexor XR, elderly, Eli Lilly, escitalopram, Lamictal, lamotrigine, Lexapro, Lilly, lithium, medication, meds, mental health, mental illness, Olanzapine, paroxetine, patients, Paxil, PCPs, prescribing, prescriptions, primary care physicians, psych hospital, psych meds, psychiatrists, psychosis, quetiapine, Schizophrenia, seniors, Seroquel, suicidal ideation, suicidal thoughts, Suicide, venlafaxine, Zyprexa
Eli Lilly’s actions continue to be appalling.
Apart from trying to hide the fact that Zyprexa induces weight gain, diabetes, and hyperglycemia, they also had sales reps encourage primary care physicians to prescribe Zyprexa for patients who did not have schizophrenia or bipolar disorder (basically off-label usage).
It seems that Lilly told marketing reps to suggest Zyprexa for dementia in the elderly. Lilly denies this, of course, since olanzapine (Zyprexa’s generic name) is not approved for that kind of use since it increases the risk of death in seniors with psychosis associated with dementia. Lilly also attempted to market olanzapine to patients with mild bipolar disorder who suffer mainly from depression. (In actuality, Zyprexa is approved to treat those who suffer from mania.)
This issue with Eli Lilly delves into precisely why I am against PCPs prescribing psychiatric medicines. Primary care physicians don’t know enough about the various psychiatric conditions to prescribe the appropriate kind of medication. This type of prescription should be left to specialists like psychiatrists. PCPs should focus on the things they deal with on a daily basis that no one else can take care of: the common cold, the flu, annual physical, etc. It should be the job of the PCP to refer a patient to a psychiatrist should they present symptoms of mental illness (depression, schizophrenia, etc.). I have been burned by having a PCP prescribe antidepressants for me and as a result, attributed my horrible experience with drugs to that.
Read the rest of this entry »
December 18, 2006 at 11:31 am (Anxiety/Stress, Celebrities, Depression, Loose Screws Mental Health News, Medicine/Meds, Mental Health/Illness, Pharma)
Tags: antidepressant, antipsychotic, anxiety, atypical, bipolar, Bipolar Disorder, Bracco, canada.com, clinical anxiety, clinical depression, clinical trials, Depression, diabetes, Dr. Melfi, Eli Lilly, high blood sugar, hyperglycemia, Lorraine Bracco, med, medications, mental health, mental illness, New York Times, Olanzapine, psych meds, Schizophrenia, side effects, survey, The Sopranos, winter, zoloft, Zyprexa
Canada.com reports that a Canadian mental health survey found that more than 75 percent of people diagnosed with clinical anxiety or depression experience a severe relapse during the winter months, namely December and January.
“Among the symptoms those people reported, more than half said they experienced ‘feelings of worthlessness,’ ‘inappropriate guilt’ and difficulty thinking or concentrating during the winter holiday season.”
The survey also found that decreased daylight hours and increased debt during the holiday season contribute to stress among those with chronic mental illness. At least the article didn’t say there was a spike in suicides…
Lorraine Bracco, known as Dr. Melfi on The Sopranos, has written a book about her struggle with clinical depression. She notes the difference between how she functioned before her depression hit and after. She cites Zoloft as the antidepressant that helped her overcome the hump and a mental realization that she needed to get help. She no longer uses antidepressants but she feels that the antidepressant got her to a place where she could find herself again, “I found my joie de vivre, my spirit, my voice.”
And finally, it’s time to be pissed off at Eli Lilly. Documents obtained by a mental health lawyer, given to The New York Times, show that Lilly execs tried to downplay the risk of obesity and hyperglycemia in Zyprexa. The two side effects can lead to a significantly increased risk for diabetes. Lilly material even included statements to sales reps telling them to downplay those risks when pitching the atypical antipsychotic to doctors. Zyprexa, Lilly’s best-selling drug, has been sold to 2 million people and has raked in $4.2 billion worldwide. The drug is primarily prescribed for schizophrenia and bipolar disorder. Of course, Lilly execs, aware that the side effects would keep patients away from the drug, downplayed the risks and even went so far as to say, “There is no scientific evidence establishing that Zyprexa causes diabetes.”
Lawsuits speaks differently, however. Lilly has agreed to pay $750 million to 8,000 people who claim that Zyprexa has caused them to develop diabetes or other medical problems. According to the Times, “thousands more suits against the company are pending.”
Read the rest of this entry »
December 17, 2006 at 12:35 am (Depression, Mental Health/Illness, Suicide)
Tags: anti-war, anti-war activism, anti-war activist, blaze, blogosphere, Blogs, Buddhist monks, Chicago, Chicago Reader, chicago sun-times, crazy, death, Depression, Donald Rumsfeld, flames, futile gesture, homicidal, immolation, malachi ritscher, mark david ritscher, martyr, martyrdom, mental illness, pagan science monitor, ritscher, Schizophrenia, schizophrenic, self-immolation, spiritual warrior, Suicide, terrorist, Vietnam War, war in Iraq
A few weeks ago, I wrote about Malachi Ritscher who immolated himself on the side of expressway in Chicago. I made this assessment:
“Only time will tell whether the blogosphere takes his self-immolating act and runs with it on the heels of ‘martyrdom.'”
I wasn’t off-base. Ritscher lit himself on fire on Friday, November 3. By Friday, November 10, Jennifer Diaz of Chicago set up a site called I heard you, Malachi in honor of his self-immolating act to bring attention to the war in Iraq.
The Pagan Science Monitor has a discussion going on about “Was Malachi Ritscher crazy?” It also had previous discussions on “A martyr for peace: Malachi Ritscher.” Much of the argument seems to be that Ritscher’s act shouldn’t bring attention to mental illness but should, rather, focus on that which he intended for it to do: shift attention to the injustice of the war in Iraq. While I understand that what he did was a symbolic gesture, it has left the few of us who got wind of the story scratching our heads, wondering, “What in the … ?!”
Read the rest of this entry »